SAHA SAURABH

CNTA CEO sells 55,000 shares ($875.6K) at $15.92; stock up 29.2% in 30 days, company posts $-26.1M net loss on $15.0M revenue.

SAHA SAURABH, CEO of Centessa Pharmaceuticals, sold 55,000 shares (55.0K shares) for $875,600.00 ($875.6K) at $15.92, reducing his holdings by 19.9% to 221,017 shares (221.0K shares). The stock has surged 29.2% over the prior 30 days and is trading at $16.06, only 15.6% below its 52-week high. His track record across all tickers shows a 76.47% well-timed sell rate over 90 days (19 prior sells, avg 90d return -5.7%), yet at this specific ticker his record is more mixed: 1 of 3 measurable same-ticker sales was well-timed at the 90-day mark, with recent sells showing +24.2%, -0.2%, and +1.5% 30-day outcomes. The company fundamentals reveal severe strain: $15.0M quarterly revenue against a $-26.1M net loss, with annual revenue growth of -100.0%, indicating the business is unprofitable and contracting sharply. A CEO sale of this scale during a 30-day rally, against a backdrop of deteriorating operational results and a track record of generally well-timed sells, warrants attention to whether the stock's recent momentum is sustainable given the underlying financial deterioration.

CEO Saha sells 55,000 CNTA shares at $12.63; holdings fall to 221,017 (from 276,017); stock down 34.7% from 52-week high.

CEO Saurabh Saha sold 55,000 shares (55.0K shares) of Centessa Pharmaceuticals on 2025-06-20 at $12.63, reducing his holdings by 19.9% to 221,017 shares. This sale occurs amid significant stock weakness: the stock is down 34.7% from its 52-week high of $19.03 and has declined 21.1% over the past 90 days. The company remains deeply unprofitable with a net loss of $26,135,000.00 on quarterly revenue of $15,000,000.00 and a -100.0% annual revenue growth rate. Within this ticker specifically, Saha's prior two measurable 90-day sale outcomes (2025-03-20 and 2025-02-20) both resulted in further declines, establishing a pattern of well-timed exits at this company; his cross-ticker track record shows 19 prior sells with an 81.25% well-timed rate, though his 90-day average return after those sales was -9.0%. This current sale represents continued reduction of exposure during a period of material stock deterioration and persistent operational losses.

CEO Saurabh Saha sells 55,000 shares of CNTA at $12.71; post-transaction holdings 221,017 shares (-19.9%)

Saurabh Saha, Chief Executive Officer, sold 55,000 shares at $12.71 on 2025-05-20, reducing his holdings by 19.9% to 221,017 shares. The transaction occurred 30.6% below the 52-week high of $19.03 and follows a recent sales pattern—he executed four sales in the prior 60 days at this ticker (2025-02-20, 2025-02-20, 2025-03-20, 2025-04-21, 2025-04-22). His cross-ticker sell track record shows a 71.43% well-timed rate over 90 days, though outcome data at CNTA specifically is still emerging; his most recent CNTA sale on 2025-03-20 showed a -26.3% 30-day return, suggesting downward pressure post-trade. The company posted $-26.1M net income on $15.0M quarterly revenue and -100.0% annual revenue growth, indicating severe financial headwinds. The frequency and volume of CEO sales warrant attention given the company's unprofitable status.

CEO Saha sells 55,000 shares (19.9% reduction) at $12.29–$12.43 as CNTA stock down 24.0% in 90 days; unprofitable fundamentals.

SAURABH SAHA, Chief Executive Officer of Centessa Pharmaceuticals, executed 2 separate sales totaling 55,000 shares for $681.6K on 2025-04-21 and 2025-04-22 at a blended average price of $12.39. This represents a 19.9% reduction in his post-transaction holdings to 221.0K shares. The timing context is material: the stock has declined 24.0% over the past 90 days and 19.6% over 30 days, currently trading 33.4% below its 52-week high of $19.03. Centessa reported a net loss of $-42.6M for its most recent full fiscal year with annual revenue growth of -100.0%, indicating the company is unprofitable and generating no revenue. At the same ticker (CNTA), Saha's prior two measurable 90-day sales outcomes both showed negative returns (−25.0% and −22.9%), establishing a 2-of-2 pattern of well-timed sells at this specific company. The current sale occurs after stock deterioration and amid fundamental headwinds, warranting close investor attention to the underlying operational trajectory.

CEO Saurabh Saha sold 55,000 shares of CNTA at $16.69 on 2025-03-20; stock now $15.75, down 17.2% from 52-week high.

CEO Saurabh Saha sold 55,000 shares (55.0K shares) at $16.69, reducing his holdings by 16.6% to 276,017 shares (276.0K shares) post-transaction. The sale occurred at a price 5.6% above the current market level of $15.75, though the stock remains -17.2% from its 52-week high of $19.03. Centessa Pharmaceuticals reported a net loss of $42.6M over its most recent full fiscal year, placing this sale in the context of a financially troubled biotech enterprise with significant annual burn. The insider's cross-ticker track record shows 16 prior sells with a 90-day well-timed rate of 66.67%, and at this specific ticker his prior 2024-12-20 sale preceded a 90-day decline of -6.6%; however, his more recent CNTA sales in January and February of 2025 saw 30-day positive returns of +3.4% and +6.3%, suggesting mixed predictive power at this ticker in particular. The sale warrants observation given the company's unprofitability, the significant reduction in CEO equity stake, and the modest forward-looking context (current 30-day performance -1.0%, 90-day -8.2%).

Director Saurabh Saha purchases 58,275 shares of CLVT at $4.36 amid -46.3% decline from 52-week high; post-purchase stake doubles to 82,016 shares

Director Saurabh Saha acquired 58,275 shares at $4.36 on 2025-03-03, more than tripling his prior 23,741-share position to 82,016 shares, representing a $254,079 open-market purchase. The transaction occurred as the stock trades -46.3% below its 52-week high and -21.0% over the past 30 days, amid fundamental headwinds: Clarivate reported a net loss of $-65.6M on revenue of $622.2M in its latest quarter, with full-year net income negative and annual revenue declining -2.7%. Saha's cross-ticker track record shows 16 prior open-market sells with a 60.00% well-timed rate, but this buy cannot be evaluated against his prior sell timing since it is a buy transaction. The magnitude of the purchase (245.5% increase in holdings) at a depressed price level warrants monitoring of whether this reflects management's assessment of valuation or strategic necessity amid the company's current operating losses.

CEO Saurabh Saha sold 55,000 CNTA shares (14.2% of holdings) for $876,087.94 across two tranches at $15.92–$16.54 on 2025-02-20.

On 2025-02-20, Centessa CEO Saurabh Saha executed two separate sales totaling 55,000 shares (14.2% of his pre-transaction holdings of 386,017 shares) at blended average price $15.93, reducing his stake to 331,017 shares and generating gross proceeds of $876,087.94. The company reported net income of $-42,566,000.00 in its most recent full fiscal year, indicating ongoing unprofitability. Within Saha's specific transaction history at CNTA, one prior measurable 90-day outcome (2024-11-22 sale) fell negative at -8.2%, while four other recent sales (Dec–Jan) remain early in their evaluation windows. His cross-ticker track record shows 14 prior sells with a 60.00% well-timed rate and positive average returns (+2.1% at 30d, +3.3% at 90d), though this broader pattern does not necessarily predict outcomes at CNTA in particular, where recent sales have yielded mixed results.

CEO sells 55,000 shares (55.0K shares) for $867,430.04 at CNTA amid unprofitable operations; 5 consecutive sells in 3 weeks.

Saurabh Saha executed 2 separate sales on 2025-01-21 totaling 55,000 shares for $867,430.04, reducing his holdings by 11.4% from 484,398 to 429,398 shares. This filing marks the 5th sale by the CEO at Centessa Pharmaceuticals in the past 3 weeks—prior sells occurred on 2024-12-20, 2024-12-06, 2024-11-22, and 2024-11-21. The company is unprofitable with net income of $-42,566,000.00, and the stock is down 4.8% over 30 days and -10.7% from its 52-week high of $18.67. The concentration and frequency of disposals alongside a capital-negative business backdrop invites examination of whether the CEO's assessment of near-term prospects has shifted materially since these sales began in November.

CEO Saurabh Saha sells 55,000 CNTA shares at $17.44 (9.6% of holdings) on 2024-12-20 as company burns $42.6M annually

Saurabh Saha, CEO of Centessa Pharmaceuticals, sold 55,000 shares ($959.1K total value) on 2024-12-20, reducing holdings from 575.7K to 520.7K shares. This follows a cluster of five insider sales at CNTA over the prior month (2024-11-13 through 2024-12-06), suggesting sustained capital deployment. The company is unprofitable with a $-42.6M net income on a $2.3B market cap, indicating ongoing cash burn. Across his broader cross-ticker history, Saha's prior 11 sales had a 0.00% well-timed rate at the 90-day mark, averaging +21.1% returns after sale (meaning stock rose post-sale), and none of his five measurable prior trades at CNTA achieved negative 90-day returns that would indicate favorable sale timing. Stock remains near its 52-week highs at 8.1% below the $18.67 peak.

CEO Saurabh Saha sold 87,496 shares of CNTA at $18.46 (Dec 6, 2024) amid fourth consecutive day of heavy selling.

SAURABH SAHA, the CEO, sold 87,496 shares (87.5K shares) on 2024-12-06 at $18.46 for $1,615,254.91 ($1.6M), reducing his position by 13.2%. This sale follows an unusual pattern: four sales in as many trading days (2024-10-23, 2024-11-13, 2024-11-20, 2024-11-21, and 2024-11-22), suggesting sustained, deliberate reduction of holdings rather than a single opportunistic exit. The timing is notable—the stock now trades at $18.67, at its 52-week high, up 16.8% in 30 days and 30.6% in 90 days. Across his cross-ticker track record, prior sells averaged a 90-day return of +47.9%, indicating those sales were poorly timed (stock rose after); his same-ticker history at CNTA shows five recent sells with only one measurable outcome (2024-10-23 posting +11.3% 30-day return). The company remains unprofitable with net income of $-42,566,000.00 ($-42.6M) for its most recent full fiscal year, yet market cap stands at $2,461,555,036.92 ($2.5B).